Effects of celecoxib on volumes of hematoma and edema in patients with primary intracerebral hemorrhage

Journal of the Neurological Sciences

Volumn 279, Issue 1-2, 2009, Pages 43-46

  Park, Hee Kwon ^a,b,c   Lee, Seung Hoon ^a   Chu, Kon ^a,b,c   Roh, Jae Kyu ^a,b,c  

^a Seoul National University Hospital   (South Korea)

^b Seoul National University   (South Korea)

^c Seoul National University   (South Korea)

Author keywords

Celecoxib; Edema; Hematoma; Primary intracerebral hemorrhage; Retrospective

Indexed keywords

CELECOXIB;

AGED; ARTICLE; BRAIN EDEMA; BRAIN HEMATOMA; BRAIN HEMORRHAGE; BRAIN SIZE; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HOSPITAL ADMISSION; HUMAN; INFORMATION PROCESSING; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BRAIN EDEMA; CEREBRAL HEMORRHAGE; FEMALE; HEMATOMA; HUMANS; MALE; MIDDLE AGED; PYRAZOLES; RETROSPECTIVE STUDIES; SULFONAMIDES; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 60949108291     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jns.2008.12.020     Document Type: Article

References (33)

1. Qureshi A.I., Tuhrim S., Broderick J.P., Batjer H.H., Hondo H., and Hanley D.F. Spontaneous intracerebral hemorrhage. N Engl J Med 344 (2001) 1450-1460
2. McGuire A.J., Raikou M., Whittle I., and Christensen M.C. Long-term mortality, morbidity and hospital care following intracerebral hemorrhage: an 11-year cohort study. Cerebrovasc Dis 23 (2007) 221-228
3. Brott T., Broderick J., Kothari R., Barsan W., Tomsick T., Sauerbeck L., et al. Early hemorrhage growth in patients with intracerebral hemorrhage. Stroke 28 (1997) 1-5
4. Lisk D.R., Pasteur W., Rhoades H., Putnam R.D., and Grotta J.C. Early presentation of hemispheric intracerebral hemorrhage: prediction of outcome and guidelines for treatment allocation. Neurology 44 (1994) 133-139
5. Clasen R.A., Huckman M.S., Von Roenn K.A., Pandolfi S., Laing I., and Clasen J.R. Time course of cerebral swelling in stroke: a correlative autopsy and CT study. Adv Neurol 28 (1980) 395-412
6. Feigin V.L., Lawes C.M., Bennett D.A., and Anderson C.S. Stroke epidemiology: a review of population-based studies of incidence, prevalence, and case-fatality in the late 20th century. Lancet Neurol 2 (2003) 43-53
7. Piriyawat P., Morgenstern L.B., Yawn D.H., Hall C.E., and Grotta J.C. Treatment of acute intracerebral hemorrhage with epsilon-aminocaproic acid: a pilot study. Neurocrit Care 1 (2004) 47-51
8. Bauer R.B., and Tellez H. Dexamethasone as treatment in cerebrovascular disease. 2. A controlled study in acute cerebral infarction. Stroke 4 (1973) 547-555
9. De Reuck J., De Bleecker J., and Reyntjens K. Steroid treatment in primary intracerebral haemorrhage. Acta Neurol Belg 89 (1989) 7-11
10. Poungvarin N., Bhoopat W., Viriyavejakul A., Rodprasert P., Buranasiri P., Sukondhabhant S., et al. Effects of dexamethasone in primary supratentorial intracerebral hemorrhage. N Engl J Med 316 (1987) 1229-1233
11. Secades J.J., Alvarez-Sabin J., Rubio F., Lozano R., Davalos A., and Castillo J. Citicoline in intracerebral haemorrhage: a double-blind, randomized, placebo-controlled, multi-centre pilot study. Cerebrovasc Dis 21 (2006) 380-385
12. Misra U.K., Kalita J., Vajpayee A., Phadke R.V., Hadique A., and Savlani V. Effect of single mannitol bolus in intracerebral hemorrhage. Eur J Neurol 14 (2007) 1118-1123
13. Haley Jr. E.C., Thompson J.L., Levin B., Davis S., Lees K.R., Pittman J.G., et al. Gavestinel does not improve outcome after acute intracerebral hemorrhage: an analysis from the GAIN International and GAIN Americas studies. Stroke 36 (2005) 1006-1010
14. Wahlgren N.G., Diez-Tejedor E., Teitelbaum J., Arboix A., Leys D., Ashwood T., et al. Results in 95 hemorrhagic stroke patients included in CLASS, a controlled trial of clomethiazole versus placebo in acute stroke patients. Stroke 31 (2000) 82-85
15. Chu K., Jeong S.W., Jung K.H., Han S.Y., Lee S.T., Kim M., et al. Celecoxib induces functional recovery after intracerebral hemorrhage with reduction of brain edema and perihematomal cell death. J Cereb Blood Flow Metab 24 (2004) 926-933
16. Zarraga I.G., and Schwarz E.R. Coxibs and heart disease: what we have learned and what else we need to know. J Am Coll Cardiol 49 (2007) 1-14
17. Bingham III C.O., Sebba A.I., Rubin B.R., Ruoff G.E., Kremer J., Bird S., et al. Efficacy and safety of etoricoxib 30 mg and celecoxib 200 mg in the treatment of osteoarthritis in two identically designed, randomized, placebo-controlled, non-inferiority studies. Rheumatology (Oxford) 46 (2007) 496-507
18. Gajraj N.M. COX-2 inhibitors celecoxib and parecoxib: valuable options for postoperative pain management. Curr Top Med Chem 7 (2007) 235-249
19. Broderick J., Connolly S., Feldmann E., Hanley D., Kase C., Krieger D., et al. Guidelines for the management of spontaneous intracerebral hemorrhage in adults: 2007 update: a guideline from the American Heart Association/American Stroke Association Stroke Council, High Blood Pressure Research Council, and the Quality of Care and Outcomes in Research Interdisciplinary Working Group. Stroke 38 (2007) 2001-2023
20. Lu Y., Wu Z., Liu C., and Wang H.H. Hepatic volumetry with PhotoShop in personal computer. Hepatobiliary Pancreat Dis Int 3 (2004) 82-85
21. Schwab J.M., and Schluesener H.J. Cyclooxygenases and central nervous system inflammation: conceptual neglect of cyclooxygenase 1. Arch Neurol 60 (2003) 630-632
22. Graham S.H., and Hickey R.W. Cyclooxygenases in central nervous system diseases: a special role for cyclooxygenase 2 in neuronal cell death. Arch Neurol 60 (2003) 628-630
23. Iadecola C. Cyclooxygenase-2 and stroke: the long and short of it. Ann Neurol 54 (2003) 141-142
24. Drachman D.B., Frank K., Dykes-Hoberg M., Teismann P., Almer G., Przedborski S., et al. Cyclooxygenase 2 inhibition protects motor neurons and prolongs survival in a transgenic mouse model of ALS. Ann Neurol 52 (2002) 771-778
25. FitzGerald G.A., and Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med 345 (2001) 433-442
26. Wang K., Tarakji K., Zhou Z., Zhang M., Forudi F., Zhou X., et al. Celecoxib, a selective cyclooxygenase-2 inhibitor, decreases monocyte chemoattractant protein-1 expression and neointimal hyperplasia in the rabbit atherosclerotic balloon injury model. J Cardiovasc Pharmacol 45 (2005) 61-67
27. Koo B.K., Kim Y.S., Park K.W., Yang H.M., Kwon D.A., Chung J.W., et al. Effect of celecoxib on restenosis after coronary angioplasty with a Taxus stent (COREA-TAXUS trial): an open-label randomised controlled study. Lancet 370 (2007) 567-574
28. Araki E., Forster C., Dubinsky J.M., Ross M.E., and Iadecola C. Cyclooxygenase-2 inhibitor ns-398 protects neuronal cultures from lipopolysaccharide-induced neurotoxicity. Stroke 32 (2001) 2370-2375
29. Iadecola C., Niwa K., Nogawa S., Zhao X., Nagayama M., Araki E., et al. Reduced susceptibility to ischemic brain injury and N-methyl-d-aspartate-mediated neurotoxicity in cyclooxygenase-2-deficient mice. Proc Natl Acad Sci U S A 98 (2001) 1294-1299
30. Nagayama M., Niwa K., Nagayama T., Ross M.E., and Iadecola C. The cyclooxygenase-2 inhibitor NS-398 ameliorates ischemic brain injury in wild-type mice but not in mice with deletion of the inducible nitric oxide synthase gene. J Cereb Blood Flow Metab 19 (1999) 1213-1219
31. Soininen H., West C., Robbins J., and Niculescu L. Long-term efficacy and safety of celecoxib in Alzheimer's disease. Dement Geriatr Cogn Disord 23 (2007) 8-21
32. Solomon S.D., Wittes J., Finn P.V., Fowler R., Viner J., Bertagnolli M.M., et al. Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis. Circulation 117 (2008) 2104-2113
33. Administration of celecoxib for treatment of intracerebral hemorrhage: a pilot study (ACE-ICH). http://clinicaltrialsgov/show/NCT00526214.